Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Expert Discusses Benefits, Next Steps With Bevacizumab in Recurrent Ovarian Cancer

April 13th 2017

Dana Chase, MD, expands on the pivotal clinical trials, managing toxicities, and the questions researchers still need to answer regarding bevacizumab for patients with ovarian cancer.

Amid PARP Advances, Chemo Remains Critical in Ovarian Cancer

April 11th 2017

Heather Dalton, MD, discusses the first-line treatment options currently available for patients with ovarian cancer, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

Surgical Approaches Continue to Evolve in Ovarian Cancer

April 10th 2017

Shana Wingo, MD, explains how surgical approaches have evolved in ovarian cancer.

Novel RAF Inhibitor Active Across Multiple Tumor Types

April 4th 2017

Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.

PARP Inhibitor Explosion Continues in Ovarian Cancer

April 1st 2017

Ursula A. Matulonis, MD, discusses the latest regulatory advances with PARP inhibitors and their continued growth in the treatment of patients with ovarian cancer.

New Genetic Variants Identified in Ovarian Cancer

March 30th 2017

Paul Pharoah, MD, PhD, discusses the significance of his research in ovarian cancer and the potential for translating genetic discoveries into meaningful clinical benefits.

FDA Grants Maintenance Olaparib Priority Review for Ovarian Cancer

March 28th 2017

The FDA has granted a priority review to a new drug application for olaparib (Lynparza) as a maintenance therapy in relapsed patients with platinum-sensitive ovarian cancer, according to AstraZeneca, the manufacturer of the PARP inhibitor.

FDA Approves Niraparib for Ovarian Cancer

March 27th 2017

The FDA has approved the PARP inhibitor niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Researcher Describes Relationship Between Neoadjuvant Chemo and Readmission in Ovarian Cancer

March 27th 2017

Emma Barber, MD, discusses the impact of neoadjuvant chemotherapy on readmission rates, and how the goal of lowering readmission rates in ovarian cancer may not always align with optimizing long-term outcomes.

Dr. Swisher on Efficacy Results of ARIEL 2 Study in Ovarian Cancer

March 24th 2017

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.

New Screening Approach Effective in High-Risk Women Who Delay Oophorectomy

March 16th 2017

Steven J. Skates, PhD, discusses the standard of care, risk-reducing salpingo-oophorectomy, for women with ovarian cancer and highlights that the best option for women who choose to postpone surgery is frequent CA125 testing with the Risk of Ovarian Cancer Algorithm.

Hormonal Maintenance Therapy Improves PFS in Low-Grade Serous Ovarian Cancer

March 16th 2017

David M. Gershenson, MD, discusses the results for a retrospective study of patients with stage II to IV low-grade serous carcinoma of the ovary or peritoneum and the next steps going forward.

Dr. Moore on the NOVA Trial for Ovarian Cancer

March 16th 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

Maintenance Chemotherapy Yields No OS Benefit in Ovarian Cancer

March 15th 2017

Maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy did not improve overall survival rates in women with ovarian cancer who had achieved complete remission.

Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer

March 15th 2017

Maintenance therapy with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed, BRCA-mutant ovarian cancer.

Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer

March 15th 2017

Christina M. Annunziata, MD, PhD, head, Translational Genomics Section, National Cancer Institute, discusses the phase II/III study of olaparib (Lynparza) and cediranib for patients with platinum-resistant ovarian cancer.

Carboplatin Hypersensitivity Linked to BRCA Deficiency in Ovarian Cancer

March 14th 2017

Treatment with a carboplatin desensitization regimen led to improved overall survival in patients with BRCA-proficient ovarian cancer.

Niraparib Effective in Ovarian Cancer, Regardless of BRCA Status

March 14th 2017

The PARP inhibitor niraparib improved progression-free survival in patients with recurrent, platinum-sensitive, high-grade ovarian cancer, regardless of BRCA status, according to a review of the phase III ENGOT-OV16/NOVA trial presented at the 2017 Society of Gynecologic Oncology Annual Meeting.

Dr. Brown on Genetic Counseling for Breast and Ovarian Cancer

March 14th 2017

Jubilee Brown, MD, obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian Cancer

March 14th 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.